$176.95
3.04% yesterday
NYSE, Nov 22, 10:10 pm CET
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

AbbVie Stock price

$176.95
-11.81 6.26% 1M
+17.34 10.86% 6M
+21.98 14.18% YTD
+38.48 27.79% 1Y
+61.30 53.00% 3Y
+90.90 105.64% 5Y
+109.17 161.07% 10Y
NYSE, Closing price Fri, Nov 22 2024
+5.22 3.04%
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

Key metrics

Market capitalization $312.70b
Enterprise Value $376.53b
P/E (TTM) P/E ratio 61.71
EV/FCF (TTM) EV/FCF 24.16
EV/Sales (TTM) EV/Sales 6.78
P/S ratio (TTM) P/S ratio 5.63
P/B ratio (TTM) P/B ratio 51.84
Dividend yield 3.55%
Last dividend (FY24) $6.29
Revenue growth (TTM) Revenue growth 0.72%
Revenue (TTM) Revenue $55.53b
EBIT (operating result TTM) EBIT $17.00b
Free Cash Flow (TTM) Free Cash Flow $15.59b
Cash position $7.29b
EPS (TTM) EPS $2.87
P/E forward 44.93
P/S forward 5.59
EV/Sales forward 6.73
Short interest 1.03%
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a AbbVie forecast:

23x Buy
70%
10x Hold
30%

Analyst Opinions

33 Analysts have issued a AbbVie forecast:

Buy
70%
Hold
30%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
55,533 55,533
1% 1%
100%
- Direct Costs 16,733 16,733
5% 5%
30%
38,800 38,800
1% 1%
70%
- Selling and Administrative Expenses 5,536 5,536
212% 212%
10%
- Research and Development Expense 7,939 7,939
5% 5%
14%
25,325 25,325
15% 15%
46%
- Depreciation and Amortization 8,325 8,325
5% 5%
15%
EBIT (Operating Income) EBIT 17,000 17,000
20% 20%
31%
Net Profit 5,081 5,081
22% 22%
9%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Positive
Seeking Alpha
about 12 hours ago
In recent days, financial market participants have remained pessimistic about AbbVie's prospects, mainly due to the data on clinical outcomes related to emraclidine. However, I believe Mr. Market overreacted to this news, given the increase in dividend payments and the full-year non-GAAP EPS. AbbVie continues to be a leader in the global immunology market, thanks in part to the strong performan...
Positive
Investors Business Daily
about 16 hours ago
AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep. The post AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback appeared first on Investor's Business Daily.
Neutral
Forbes
2 days ago
Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 50,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today